Exciting to see new studies like this one* supporting our findings that targeting MDM2/MDMX could enhance immunotherapy efficacy by overcoming resistance. Our research in 2020 Wafik S. El-Deiry, MD, PhD, FACP lab highlighted MDM2’s pivotal role in immunotherapy resistance.**

OncoDaily Jacob J. Adashek, DO Med by Cell Press MCW Cancer Center Razelle Kurzrock, MD ScienceDirect Excellent insight on advancing cancer treatment through innovation! Collaboration and research are key. Kudos to all involved!

OncoDaily Jacob J. Adashek, DO Med by Cell Press MCW Cancer Center Razelle Kurzrock, MD ScienceDirect Fantastic insights, OncoDaily! Jacob J. Adashek, DO's work shows how collaboration in #CancerResearch , like in #liquidbiopsies , drives innovation.

Dr Timothy Yap #esmobreast24 mini-oral abstract on IND CDK4 inhibitor PF722 (Pfizer Oncology Medical drug). Pts had prior CDK4/6i & prior fulvestrant. Side effects were mainly 🩸 18% grade 3 neutropenia; diarrhea 🚽 but almost all grade 1; nausea, again mainly grade 1.

A labor of love I created for NCI PDQ - Agnostic Cancer Therapies Treatment Summary Tissue - Jacob J. Adashek, DO
@HopkinsKimmel National Cancer Institute HopkinsHemOncFellowship Kristen A. Marrone, MD
oncodaily.com/65638.html

#Cancer #NCI #OncoDaily #Oncology #PDQ #JohnsHopkinsHospital

Only 10 patients but provocative data from Dr. Marshall (Hopkins) et al on clonal hematopoiesis emerging in ppl treated with LuPSMA. Clearly a topic of future research focus. Need randomized or comparative data to understand relevance vs other treatments. onlinelibrary.wiley.com/doi/10.1002/pr…

Shabbat Shalom. Non-Jewish friends have reached out to express their concerns for the rise in antisemitism. Many want to help but don’t know how. Checking in and showing support means far more than you can imagine to your Jewish friends. ✡️💪

OncoDaily Jacob J. Adashek, DO Johns Hopkins Kimmel Cancer Center National Cancer Institute HopkinsHemOncFellowship Kristen A. Marrone, MD Brilliant! Agnostic cancer therapies embody oncology's future—bridging advanced research and impactful patient care. Kudos on this contribution! #Oncology

So excited to share our work on 1L osimertinib for uncommon ex19del and compound EGFRm in NSCLC! Huge thanks to Susan Combs Scott, MD, Kristen A. Marrone, MD, Matthew Guo, Johns Hopkins Thoracic Oncology for their mentorship on this project :) sciencedirect.com/science/articl…

Jacob J. Adashek, DO Med by Cell Press MCW Cancer Center Razelle Kurzrock, MD Ivy Riano, M.D. Fernando Diaz, MD Abdelali (Ali) Majdi Nirmal Raut Yan Leyfman, MD 𝐂𝐡𝐚𝐧𝐝𝐥𝐞𝐫 𝐏𝐚𝐫𝐤 𝐌𝐃 𝐅𝐀𝐂𝐏 Nicole Kuderer, MD, MS, FASCO 🌎🇺🇸🇪🇺🇺🇦🌏 Medics4RareDiseases RASopathies Network Tuberous Sclerosis Association With the 1st FAKi approval FDA Oncology
on the horizon, it will be interesting to follow its evolution in disease treatment 💊 besides #cancer . #CVD #cardiovascular ❤️ #diabetes , in particular!
Matthew Katz, MD 🟦 International Atherosclerosis Society (IAS) European Atherosclerosis Society
🔻
x.com/crozrx/status/…

Why are we smiling😁? Because we like our jobs in academia and got invited to speak about it at the place to be during #ASCO24 : The ASCO TECAG Trainee Lounge

Join us for this Panel Discussion on Careers in Oncology Academia with Neeraj Agarwal, MD, FASCO Huntsman Cancer Institute Amanda Nizam, MD

Three ways to approach tumors with undruggable fusions
1. Look at RNA expression
2. Look at immunomics for immunotherapy
3. Look at IHCs and consider an ADC or other matched therapy

Jacob J. Adashek, DO Med by Cell Press MCW Cancer Center Razelle Kurzrock, MD Ivy Riano, M.D. Fernando Diaz, MD Nirmal Raut Yan Leyfman, MD 𝐂𝐡𝐚𝐧𝐝𝐥𝐞𝐫 𝐏𝐚𝐫𝐤 𝐌𝐃 𝐅𝐀𝐂𝐏 Nicole Kuderer, MD, MS, FASCO 🌎🇺🇸🇪🇺🇺🇦🌏 Medics4RareDiseases RASopathies Network Tuberous Sclerosis Association Being deeply involved with individuals living with rare conditions, these scientific bridges are so important. And it goes both ways.
Thank you for the great paper.

Jacob J. Adashek, DO Med by Cell Press MCW Cancer Center Razelle Kurzrock, MD Ivy Riano, M.D. Fernando Diaz, MD Abdelali (Ali) Majdi Nirmal Raut Yan Leyfman, MD 𝐂𝐡𝐚𝐧𝐝𝐥𝐞𝐫 𝐏𝐚𝐫𝐤 𝐌𝐃 𝐅𝐀𝐂𝐏 Nicole Kuderer, MD, MS, FASCO 🌎🇺🇸🇪🇺🇺🇦🌏 Medics4RareDiseases Tuberous Sclerosis Association Great figures . So glad you are bringing needed attention to this idea.

Cancer divided by site, united by pathways!
Razelle Kurzrock, MD called cancer by site of origin “accident of history” tethered to anatomy based treatment!
Time to evolve?
Provocative 🧐👉🏻
Forget lung, breast or prostate cancer: why tumour naming needs to change nature.com/articles/d4158…

Accident of history. Because light microscope was discovered 400 years ago

Jacob J. Adashek, DO Med by Cell Press MCW Cancer Center Razelle Kurzrock, MD Ivy Riano, M.D. Fernando Diaz, MD Abdelali (Ali) Majdi Nirmal Raut Yan Leyfman, MD 𝐂𝐡𝐚𝐧𝐝𝐥𝐞𝐫 𝐏𝐚𝐫𝐤 𝐌𝐃 𝐅𝐀𝐂𝐏 Nicole Kuderer, MD, MS, FASCO 🌎🇺🇸🇪🇺🇺🇦🌏 Medics4RareDiseases RASopathies Network Tuberous Sclerosis Association Amazing review!

Jacob J. Adashek, DO Med by Cell Press MCW Cancer Center Razelle Kurzrock, MD Ivy Riano, M.D. Fernando Diaz, MD Abdelali (Ali) Majdi Nirmal Raut Yan Leyfman, MD 𝐂𝐡𝐚𝐧𝐝𝐥𝐞𝐫 𝐏𝐚𝐫𝐤 𝐌𝐃 𝐅𝐀𝐂𝐏 Medics4RareDiseases RASopathies Network Tuberous Sclerosis Association Thinking outside the box indeed 👍👍

So important 🙌🙌

Jacob J. Adashek, DO Med by Cell Press MCW Cancer Center Razelle Kurzrock, MD Ivy Riano, M.D. Fernando Diaz, MD Abdelali (Ali) Majdi Nirmal Raut 𝐂𝐡𝐚𝐧𝐝𝐥𝐞𝐫 𝐏𝐚𝐫𝐤 𝐌𝐃 𝐅𝐀𝐂𝐏 Nicole Kuderer, MD, MS, FASCO 🌎🇺🇸🇪🇺🇺🇦🌏 Medics4RareDiseases RASopathies Network Tuberous Sclerosis Association Amazing work as always!

Jacob J. Adashek, DO Med by Cell Press MCW Cancer Center Razelle Kurzrock, MD Ivy Riano, M.D. Abdelali (Ali) Majdi Nirmal Raut Yan Leyfman, MD 𝐂𝐡𝐚𝐧𝐝𝐥𝐞𝐫 𝐏𝐚𝐫𝐤 𝐌𝐃 𝐅𝐀𝐂𝐏 Nicole Kuderer, MD, MS, FASCO 🌎🇺🇸🇪🇺🇺🇦🌏 Medics4RareDiseases RASopathies Network Tuberous Sclerosis Association Congratulations to and your team, Jacob! I look forward to reading it this weekend! 🔥